Senior Global Late-Stage Partnering Manager

Ipsen ADR; Cambridge (MA); On-site; USD 113,000 - 165,000; Full time

Job summary

Ipsen is seeking a Senior Manager for Global Late-Stage Partnering in Cambridge, MA to lead external opportunity intelligence across Oncology, Rare Diseases, and Neuroscience. You will translate science, clinical, and commercial insights into strategic analyses to guide portfolio planning and partnering decisions.

The role supports late‑stage transactions and coordinates cross‑functional input from R&D, Medical Affairs, Commercial, Finance, and Legal, while maintaining a proactive view of

Qualifications

• 3-7 years of experience in business development, competitive intelligence, corporate strategy, management consulting, equity research, portfolio strategy, or biopharmaceutical industry.
• Experience evaluating external assets, technologies, or pipeline opportunities is highly desirable.
• Bachelor's or Master's degree in a scientific, medical, or business discipline required.
• Advanced scientific degree (PhD, PharmD, MD) and/or MBA preferred.

Responsibilities

• External Opportunity Landscape Management: Own and maintain a comprehensive, continuously updated landscape of late‑stage partnering opportunities across Oncology, Rare Diseases, and Neuroscience.
• Develop and manage a systematic process for identifying, tracking, evaluating, and prioritizing external assets and companies of strategic interest.
• Monitor the external environment to identify emerging opportunities, competitive developments, strategic transactions, and shifts in market dynamics that may impact Ipsen's business development priorities.
• Establish and maintain tools, databases, dashboards, and reporting mechanisms that provide visibility into the external opportunity universe.
• Serve as the internal owner of the external opportunity universe and ensure opportunity assessments remain current, organized, and actionable.
• Monitoring Program Value Inflection Points: Track, analyze, and maintain a forward‑looking view of key clinical, regulatory, commercial, corporate, and financing milestones for programs and companies of strategic interest.
• Proactively communicate important developments and their potential implications to the Global Late‑Stage Partnering team and relevant internal stakeholders.
• Internal Stakeholder Engagement and Insight Generation: Build and maintain strong working relationships with leaders across Oncology, Rare Diseases, and Neuroscience.
• Serve as the primary coordinator for gathering, consolidating, and maintaining Ipsen's perspectives on externally monitored assets and companies.
• Maintain institutional knowledge of previous opportunity evaluations and strategic discussions.
• Strategic Business Development and Transaction Support: Provide ad hoc support on selected late‑stage business development transactions, including opportunity assessments, diligence preparation, competitive analyses, valuation support, and preparation of internal decision‑making materials.
• Participate in transaction teams as appropriate, gaining exposure to evaluation and execution of licensing, acquisition, and collaboration opportunities.
• While transaction support will provide opportunities, the primary focus is identification, monitoring, prioritization, and strategic assessment of external partnering opportunities across Ipsen's therapeutic areas.

Skills

Business development

Competitive intelligence

Strategic analysis

Cross-functional collaboration

Education

Bachelor's degree in scientific/medical/business discipline

Master's degree in scientific/medical/business discipline

Advanced degree (PhD/MD/PharmD) or MBA preferred

Job description

Ipsen is seeking a Senior Manager for Global Late-Stage Partnering in Cambridge, MA to lead external opportunity intelligence across Oncology, Rare Diseases, and Neuroscience. You will translate science, clinical, and commercial insights into strategic analyses to guide portfolio planning and partnering decisions.

The role supports late‑stage transactions and coordinates cross‑functional input from R&D, Medical Affairs, Commercial, Finance, and Legal, while maintaining a proactive view of